Login
$LXEO
$3.23 +$0.00 (0.0%) After hours

$LXEO 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

29 Sep 2026 8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities

At the effective time of the Merger (the “Effective Time”), each outstanding share of Mantle capital stock (other than shares held by Mantle as treasury shares, shares held by Lexeo or Merger Sub, and Dissenting Shares) was converted int...

22 Sep 2026 8-K: Entry into a Material Definitive Agreement; Other Events

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

12 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027

29 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 25, 2026, Lexeo Therapeutics, Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M...

15 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Lexeo Therapeutics Corporate Overview June 2026 Exhibit 99.3

11 May 2026 8-K: Results of Operations and Financial Condition; Other Events

SUNRISE-FA2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback

30 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 28, 2026 (the “Appointment Date”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”). Dr. Sepp-Lorenzino will serve as a director with a term of office exp...

30 Mar 2026 8-K: Results of Operations and Financial Condition; Other Events

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following

05 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 30, 2026, Lexeo Therapeutics, Inc. (the “Company”) entered into a Transition and Consulting Agreement (the “Transition Agreement”) with Dr. Adler, effective February 1, 2026, pursuant to which Dr. Adler stepped down from his r...

27 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 27, 2026, Lexeo Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Jose Manuel Otero, Ph.D., the Company’s current Chief Technical Officer, to serve as Chief Operati...

12 Jan 2026 8-K: Regulation FD Disclosure; Other Events

LX2020 generally well tolerated across ten participants with no clinically significant complement activation

05 Nov 2025 8-K: Results of Operations and Financial Condition

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier

17 Oct 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 16, 2025, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this A...

07 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

14 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia

30 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2025, Lexeo Therapeutics, Inc. (the “Company”) held its virtual 2025 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M...

27 May 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 27, 2025, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this Agree...

12 May 2025 8-K: Results of Operations and Financial Condition

Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study

07 Apr 2025 8-K: Regulation FD Disclosure; Other Events

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support